VIZ Plain Royal Blue Adjustable Baseball Cap

Product Information

As COVID-19 vaccines are administered across Canada, our safety monitoring is ongoing. The Public Health Agency of Canada, Health Canada, and provincial and territorial health authorities continue to: The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) Health Canada's independent drug review process is recognized around the world for its high standards and rigor. Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. The benefits must also outweigh any risks.

The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label. The mRNA sequence from Moderna Spikevax ®COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.4/5 variants. Other ingredients years and older (50 micrograms at least 4 months after their previous dose) Moderna Spikevax ®COVID-19 vaccine, Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination.

Find detailed technical information such as the product monograph and the regulatory decision summary: The Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. This means that the booster is expected to offer protection against this variant. Its safety and effectiveness in people younger than 6 months has not yet been established. Effectiveness Health care providers must report possible reactions following vaccination to their local public health authority. The public health authority then reports them to the Public Health Agency of Canada.

The safety and effectiveness of the Moderna Spikevax ® Bivalent COVID-19 vaccine(Original/Omicron BA. 4/5) is based on studies of Spikevax ® Bivalent (Original/Omicron BA.1). thanks for the tremendous contribution slewman. out of interest where did you get all the colours from? Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen.

The bivalent Original/Omicron BA.4/5 0.1 mg/mL multi-dose vial has a royal blue plastic cap and grey label. The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Monovalent COVID-19 vaccine (Omicron XBB.1.5 subvariant) The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5)